Abigale Tablet
Product Images NDC 70700-330

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Abigale (NDC 70700-330). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Estradiol Structural Formula (Image 01)

Estradiol Structural Formula (Image 01)
FDA Label Image

Norethindrone Acetate Structural Formula (Image 02)

Norethindrone Acetate Structural Formula (Image 02)
FDA Label Image

Figure 1a: Mean Baseline-uncorrected Estradiol And Estrone Serum Concentration-time Profiles Following Multiple Doses Of Estradiol And Norethindrone Acetate Tablets 1 mg/0.5 mg (n=24) (Image 03)

Figure 1a: Mean Baseline-uncorrected Estradiol And Estrone Serum Concentration-time Profiles Following Multiple Doses Of Estradiol And Norethindrone Acetate Tablets 1 mg/0.5 mg (n=24) (Image 03)
FDA Label Image

Figure 1b: Mean Baseline-uncorrected Norethindrone Serum Concentration-time Profile Following Multiple Doses Of Estradiol And Norethindrone Acetate Tablets 1 mg/0.5 mg (n=24) (Image 04)

Figure 1b: Mean Baseline-uncorrected Norethindrone Serum Concentration-time Profile Following Multiple Doses Of Estradiol And Norethindrone Acetate Tablets 1 mg/0.5 mg (n=24) (Image 04)
FDA Label Image

Figure 2: Mean Weekly Number Of Moderate And Severe Hot Flushes In A 12-week Study (Image 05)

Figure 2: Mean Weekly Number Of Moderate And Severe Hot Flushes In A 12-week Study (Image 05)
This text provides information about the frequency of hot flushes per week in a study involving different treatments like placebo, 1 mg of Estradiol, and a combination of Estradiol and norethindrone acetate tablets (1mg/0.5 mg). The data is presented over a 12-week period.*
FDA Label Image

Figure 3: Mean Number Of Moderate To Severe Hot Flushes For Weeks 0 Through 12 (Image 06)

Figure 3: Mean Number Of Moderate To Severe Hot Flushes For Weeks 0 Through 12 (Image 06)
FDA Label Image

Figure 4: Patients Treated With Estradiol And Norethindrone Acetate Tablets 1 mg/0.5 mg With Cumulative Amenorrhea Over Time Percentage Of Women With No Bleeding Or Spotting At Any Cycle Through Cycle 13 Intent To Treat Population, Locf (Image 07)

Figure 4: Patients Treated With Estradiol And Norethindrone Acetate Tablets 1 mg/0.5 mg With Cumulative Amenorrhea Over Time Percentage Of Women With No Bleeding Or Spotting At Any Cycle Through Cycle 13 Intent To Treat Population, Locf (Image 07)
FDA Label Image

Figure 5: Patients Treated With Estradiol And Norethindrone Acetate Tablets 0.5 mg/0.1 mg With Cumulative Amenorrhea Over Time Percentage Of Women With No Bleeding Or Spotting At Any Cycle Through Cycle 6, Intent To Treat Population, Locf (Image 08)

Figure 5: Patients Treated With Estradiol And Norethindrone Acetate Tablets 0.5 mg/0.1 mg With Cumulative Amenorrhea Over Time Percentage Of Women With No Bleeding Or Spotting At Any Cycle Through Cycle 6, Intent To Treat Population, Locf (Image 08)
FDA Label Image

Figure 6: Percentage Change In Bone Mineral Density (bmd) ± Sem Of The Lumbar Spine (l1-l4) For Estradiol And Norethindrone Acetate Tablets 1 mg/0.5 mg And Estradiol 0.5 mg (intent To Treat Analysis With Last Observation Carried Forward) (Image 09)

Figure 6: Percentage Change In Bone Mineral Density (bmd) ± Sem Of The Lumbar Spine (l1-l4) For Estradiol And Norethindrone Acetate Tablets 1 mg/0.5 mg And Estradiol 0.5 mg (intent To Treat Analysis With Last Observation Carried Forward) (Image 09)
The text is not clear and appears to be garbled. Therefore, the description is not available.*
FDA Label Image

Patient Information Figure 1 (Image 10)

Patient Information Figure 1 (Image 10)
FDA Label Image

Estradiol And Noretindrone Acetate Tablets 0.5 mg/0.1 mg Label (Image 11)

Estradiol And Noretindrone Acetate Tablets 0.5 mg/0.1 mg Label (Image 11)
This text provides information about a medication named "Abigale™ Lo" which consists of Estradiol and Norethindrone Acetate Tablets. The tablets are in blister packs containing 28 tablets each, with a total of 3 pouches. The medication has a strength of 0.5 mg/0.1 mg. The NDC (National Drug Code) for this medication is 70700-303-85.*
FDA Label Image

Estradiol And Noretindrone Acetate Tablets 1 mg/0.5 mg Label (Image 12)

Estradiol And Noretindrone Acetate Tablets 1 mg/0.5 mg Label (Image 12)
This is a product description for Abigale™, which is a medication containing Estradiol and Norethindrone Acetate in tablet form. Each pouch contains one blister pack of 28 tablets with a dosage of 1 mg Estradiol and 0.5 mg Norethindrone Acetate. It is important to follow the prescribed dosage instructions when using this medication.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.